Why the study?
Does FGF21 prevent DOX-induced cardiotoxicity in preclinical models?
Does FGF21 prevent DOX-induced cardiotoxicity in preclinical models?
FGF21 protects against doxorubicin-induced cardiotoxicity in preclinical models by activating the SIRT1/LKB1/AMPK pathway.
No takes yet. Share an insight, caveat, or question.
Does not support clinical use of FGF21 for doxorubicin cardiotoxicity; leaves open translational human trials.
Wang et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: